Nanoparticles containing amino acid and preparation method and application thereof
By developing amino acid-containing nanoparticles, using the combination of polydopamine and alkaline amino acids, the problem of poor drug stability in spinal cord injury treatment was solved, the pH balance of spinal cord tissue and neuronal repair were achieved, and the motor function after spinal cord injury was significantly improved. and neuroprotective effects.
Patent Information
- Application Number
- CN202411145041.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art has problems such as poor stability of drugs in the vascular system and accumulation of off-target organs when treating spinal cord injuries, resulting in poor treatment effects and difficulty in effectively repairing neurological functions.
Develop a nanoparticle containing amino acids to form nanoparticles through the binding of polydopamine and alkaline amino acids, which are used to restore the pH balance of spinal cord tissue and repair neurons, inhibit cell apoptosis, and improve the acidic microenvironment after spinal cord injury.
Nanoparticles have good biocompatibility and can effectively improve the acidic microenvironment of tissue after spinal cord injury, promote motor function recovery, protect and repair damaged neurons, inhibit cell apoptosis, and provide new therapeutic ideas.
Smart Images

Figure CN119015231A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical technology, and in particular to amino acid-containing nanoparticles and a preparation method and application thereof. Background Art
[0002] Spinal cord injury (SCI) is one of the serious central nervous system diseases that causes sensory, motor and autonomic dysfunction in patients. Its high disability rate brings a heavy burden to the quality of life, life expectancy, family and society of patients. Global statistics show that there are about 250,000 to 500,000 new cases of SCI each year, and the trend is increasing. However, less than 1% of patients can fully recover their neurological function, and up to 45% of patients eventually develop incomplete quadriplegia.
[0003] SCI can be divided into two major stages: primary and secondary injury. Primary injury originates from the initial trauma, while secondary injury is caused by a series of harmful reactions after the initial injury, involving ischemia, hypoxia, thrombosis, and oxidative stress. These events stimulate complex molecular and cellular responses, including the release of inflammatory mediators. This not only aggravates local cell damage, but also spreads the impact of the injury to a wider range through the effects of the nervous system and blood circulation.
[0004] Most of the existing drugs for the pathophysiology of SCI have problems such as poor stability in the vascular system and accumulation in off-target organs, which results in the inability of drugs with therapeutic effects in preclinical trials to be converted into accumulation and regeneration improvement in patient tissues. Therefore, it is of great significance to develop effective treatment options to repair neurological function after SCI. Summary of the invention
[0005] In view of the above problems, the purpose of the present invention is to provide a new drug as a treatment for spinal cord injury. The present invention provides an amino acid-containing nanoparticle and a preparation method and application thereof; the nanoparticle has good biocompatibility and is used to prepare a drug for treating spinal cord injury. It has the effect of restoring the pH balance of spinal cord tissue and has the effect of treating spinal cord injury, providing a new treatment idea for the clinical treatment of spinal cord injury.
[0006] In order to achieve the above object, the present invention provides, in a first aspect, an amino acid-containing nanoparticle, wherein the nanoparticle comprises polydopamine and a basic amino acid loaded on the polydopamine.
[0007] The second aspect of the present invention provides a method for preparing the amino acid-containing nanoparticles of the present invention, the method comprising:
[0008] In a solvent, polydopamine and basic amino acid are mixed and stirred, solid-liquid separation is performed to remove liquid, and drying is performed.
[0009] The third aspect of the present invention provides a use of the nanoparticles of the present invention in the preparation of a drug for treating spinal cord injury.
[0010] A fourth aspect of the present invention provides a use of the nanoparticles of the present invention in the preparation of a drug for improving motor function of spinal cord injury.
[0011] A fifth aspect of the present invention provides a use of the nanoparticles of the present invention in the preparation of a drug for protecting and / or repairing spinal cord neurons.
[0012] A sixth aspect of the present invention provides a use of the nanoparticles of the present invention in the preparation of a drug for inhibiting cell apoptosis.
[0013] Through the above technical scheme, the inventors of the present invention found that the nanoparticles of the present invention have good biocompatibility, and the amino acid-containing nanoparticles are used to prepare drugs for treating SCI, which have neuroprotective effects and the effect of restoring the pH balance of spinal cord tissue, and are particularly suitable for targeted treatment of the problem of acidosis of tissues surrounding the spinal cord caused by SCI.
[0014] It is speculated that inflammation and tissue damage caused by SCI reduce local blood flow, aggravate ischemia and hypoxia, lead to energy metabolism disorders, promote the accumulation of large amounts of lactic acid and other acidic substances, and ultimately lead to tissue acidosis. In the first week after SCI, the tissue pH value decreases significantly. This acidosis phenomenon is particularly severe in the injured area and extends to the proximal areas of the cervical spine and lumbar cord. The acidic environment has a wide range of effects on cell function, such as interfering with enzyme activity, protein stability and signal transduction, activating inflammatory cells such as macrophages and microglia, releasing inflammatory factors and cytokines, and aggravating local inflammation and tissue damage. Acidic conditions cause immune response disorders by changing immune cell function and immune response. Severe and persistent acidosis has a significant neurotoxic effect on neurons, ultimately leading to programmed cell death and destruction of synaptic connections. The formation of an acidic microenvironment in SCI and other central nervous system diseases is the result of complex pathophysiological changes, which aggravates the damage of neural tissue and hinders the recovery process after injury. The amino acid-containing nanoparticles of the present invention can regulate the acidic microenvironment and restore the pH balance of tissues; they can improve the damage of neuronal cells and inhibit cell apoptosis to achieve the treatment of spinal cord injury.
[0015] The amino acid-containing nanoparticles of the present invention are used to prepare drugs for treating spinal cord injury, especially to prepare drugs for improving the motor function of spinal cord injury, to prepare drugs for protecting and / or repairing spinal cord neurons, and to prepare drugs for inhibiting cell apoptosis. They can effectively improve the acidic microenvironment of tissues after spinal cord injury, and have the effects of promoting motor function recovery, protecting and repairing damaged nerves, and inhibiting cell apoptosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is a SEM image of Lys-PDA and PDA in an embodiment of the present invention;
[0017] Figure 2 1 is a Malvern particle size detection result diagram of Lys-PDA and PDA in an embodiment of the present invention; it is a Malvern particle size detection diagram and a particle size columnar statistical diagram respectively;
[0018] Figure 3 is a near infrared spectra of Lys-PDA and PDA in an embodiment of the present invention;
[0019] Figure 4 is the standard curve of the concentration of Lys aqueous solution in the embodiment of the present invention;
[0020] Figure 5 is the release curve of Lys in the embodiment of the present invention;
[0021] Figure 6 : is a diagram showing the BCECF-AM fluorescent staining results of frozen sections of spinal cord tissue of each group of mice in the embodiment of the present invention; Figure 6 A is the BCECF-AM fluorescence staining image of the frozen sections of spinal cord tissue of each group of mice on the 1st and 28th days; Figure 6 B is the fluorescence intensity bar chart on day 1; Figure 6 C is the fluorescence intensity bar chart on the 28th day;
[0022] Figure 7 is a graph of behavioral evaluation of mice in each group in the embodiment of the present invention; Figure 7 A is the footprint analysis of mice in each group at 28 days; Figure 7 B is a bar chart showing the BMS scores of mice in each group from 1 to 28 days; Figure 7 C is the bar chart of forefoot step length on the 28th day;
[0023] Figure 8 This is an H&E staining image of the spinal cord tissue sections of each group of mice in the embodiment of the present invention;
[0024] Fig. 9 : is a graph showing the Nissl staining results of the neurons of each group of mice in the embodiment of the present invention; Fig. 9 A is the Nissl staining of spinal cord tissue section; Fig. 9 B is a bar chart showing the number of Nissl bodies after staining;
[0025] Fig.10 This is a TUNEL staining image of spinal cord tissue sections of each group of mice in the embodiment of the present invention; Fig.10 A is the fluorescence image of TUNEL staining; Fig.10 B is a quantitative bar graph of mean fluorescence intensity;
[0026] Fig.11 1 is a graph showing the expression of Bax and bcl-2 proteins in each group of mice in the present invention; Fig.11 A is the Western Blot detection of Bax and bcl-2 protein expression; Fig.11 B is a quantitative bar chart of bcl-2 expression level. Fig.11 C is a quantitative bar chart of Bax expression levels;
[0027] Fig.12 These are H&E staining images of the heart, liver, spleen, lung, and kidney of mice in different groups in the examples of the present invention. DETAILED DESCRIPTION
[0028] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0029] In the present invention, statistical analysis was performed by Graphpad prism 9.0.0 software, and Shapiro-Wilk was used to detect the normality of the data before data statistics. Normal data were statistically analyzed using one-way analysis of variance (Analysis of Variance, ANOVA) and TUKEY-Kramer multiple comparison method, and the data were expressed as mean ± standard deviation. Non-normal distribution data were analyzed using the nonparametric Mann-Whitney U method, and the data were expressed as median and interquartile range. When the accompanying drawings were column graphs, they were marked as statistically significant differences analysis: * refers to P < 0.05, ** refers to P < 0.01, *** refers to P < 0.001, and ns refers to no significant difference, and when P < 0.05, the difference was considered to be statistically significant.
[0030] The first aspect of the present invention provides an amino acid-containing nanoparticle, which includes polydopamine and a basic amino acid loaded on the polydopamine. The nanoparticle of the present invention has good biocompatibility, is used to prepare a drug for treating spinal cord injury, has the effect of restoring the pH balance of spinal cord tissue, and has the effect of treating spinal cord injury.
[0031] In the amino acid-containing nanoparticles of the present invention, the amino acids are adsorbed onto the surface of polydopamine through the adhesion property of polydopamine. According to a preferred embodiment of the present invention, the amino acids are wrapped on the surface of polydopamine in the form of a film to form a white film-like covering layer.
[0032] According to a preferred embodiment of the present invention, the basic amino acid is selected from one or more of arginine, lysine and histidine; more preferably, the basic amino acid is lysine.
[0033] According to a preferred embodiment of the present invention, the polydopamine is a homopolymer of dopamine hydrochloride oxidatively polymerized under alkaline conditions.
[0034] In the present invention, the average particle size of the amino acid-containing nanoparticles can be selected in a wide range, which is for exemplary purposes only and does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the average particle size of the nanoparticles is 120-200 nm.
[0035] In the context of the present invention, including the following examples, a Malvern ZS90 particle size tester is used to perform particle size analysis on amino acid-containing nanoparticles and polydopamine using a dynamic light scattering method to measure the particle size of the nanoparticles and polydopamine, and the average value of 5 measured values is the average particle size of the nanoparticles.
[0036] The second aspect of the present invention provides a method for preparing the amino acid-containing nanoparticles of the present invention, the method comprising:
[0037] In a solvent, polydopamine and alkaline amino acids are mixed and stirred, solid-liquid separation is performed to remove the liquid, and drying is performed. The amino acid-containing nanoparticles prepared by the above preparation method have good biocompatibility, are used to prepare a drug for treating spinal cord injury, have the effect of restoring the pH balance of spinal cord tissue, and have the effect of treating spinal cord injury.
[0038] According to a preferred embodiment of the present invention, the loading rate of the basic amino acid is 68.89%±0.5%.
[0039] In the present invention, there is no particular limitation on the stirring conditions, and conventional stirring conditions in the art may be used. This is for exemplary purposes only, but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the stirring conditions include: a stirring temperature of 25-50°C; and a stirring time that can be determined based on actual conditions, generally 12-36 hours.
[0040] In the present invention, the types of the solvents can be selected from a wide range, which is for exemplary purposes only, but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the solvent is selected from water and / or ethanol; in the embodiments of the present invention, water is used to exemplify the advantages of the present invention, but does not limit the scope of the present invention.
[0041] In the present invention, there is no particular limitation on the drying method of the amino acid-containing nanoparticles. The present invention uses freeze-drying as an example to illustrate the advantages of the present invention; however, the scope of the present invention is not limited thereby.
[0042] In the present invention, as long as the solid-liquid mixture of polydopamine and basic amino acids can be separated, the separation method is not particularly limited, for example, centrifugation can be used for separation; the centrifugation conditions are not particularly limited, and conventional conditions in the art are sufficient, which is illustrative but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the centrifugation is ultracentrifugation, and the conditions include: the centrifugation speed is 12000-18000rpm / min; the centrifugation time is 5-15min; in the embodiment of the present invention, centrifugation at 15000rpm / min for 10min is used to exemplarily illustrate the advantages of the present invention, but does not limit the scope of the present invention.
[0043] According to a preferred embodiment of the present invention, the present invention provides a method for preparing the polydopamine of the present invention, the method comprising: polymerizing dopamine hydrochloride in the presence of an alkali solution, separating to obtain a solid, and drying. The polydopamine prepared by the above preparation method is used to prepare amino acid-containing nanoparticles with good biocompatibility and biodegradability.
[0044] In the amino acid-containing nanoparticles, polydopamine is used as a carrier and has the following advantages: (1) Polydopamine can prolong the effective blood concentration time of amino acids; (2) Polydopamine itself can regulate the immune population to anti-inflammatory and pro-regenerative phenotypes through a multimodal mechanism that affects multiple inflammatory responses in the absence of drugs; (3) The preparation conditions of polydopamine are simple and the synthesis does not require organic solvents, which facilitates research and application in biomedicine.
[0045] In the present invention, dopamine hydrochloride is added in the form of a solution, and the mass concentration range of the dopamine hydrochloride solution is relatively wide. This is for exemplary purposes only, but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the mass concentration of the dopamine hydrochloride solution is 20-30 mg / mL.
[0046] In the present invention, there is no particular limitation on the type of solvent used for the synthesis of polydopamine, and any conventional solvent in the art can achieve the purpose of the present invention, such as water and / or ethanol. According to a preferred embodiment of the present invention, the solvent is a mixed solution of water and ethanol, and preferably, the volume ratio of water to ethanol is 1:0.1-10.
[0047] In the present invention, the types of alkali solution can be selected from a wide range, which is exemplary but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the alkali solution is selected from ammonia water and / or sodium hydroxide solution; more preferably ammonia water.
[0048] In the present invention, the concentration range of the alkali in the alkali solution is relatively wide, which is illustrative, but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, when the alkali solution is selected from ammonia water, the mass concentration of the ammonia water is 25wt%-28wt%; in the embodiment of the present invention, ammonia water with a concentration of 30wt% is used to illustrate the advantages of the present invention, but does not limit the scope of the present invention.
[0049] In the present invention, as long as the polymerized polydopamine can be separated from the liquid phase, the separation form is not particularly limited. The present invention uses centrifugation to exemplify the advantages of the present invention; the centrifugation conditions are not particularly limited, and conventional conditions in the field can be used. This is an exemplary description, but it does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the centrifugation conditions include: a centrifugal speed of 12000-15000 rpm / min; a centrifugation time of 5-15 min.
[0050] According to a specific embodiment of the present invention, the number of centrifugation is not particularly limited. For example, in the embodiment of the present invention, the bottom sediment after centrifugation is washed and then the above centrifugation operation is repeated.
[0051] In the present invention, there is no particular limitation on the drying method of the polydopamine. The present invention uses freeze drying to exemplify the advantages of the present invention; however, the scope of the present invention is not limited thereby.
[0052] In the present invention, the average particle size of the polydopamine can be selected in a wide range, which is for exemplary purposes only, but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the average particle size of the polydopamine is 100-200 nm.
[0053] The third aspect of the present invention provides a use of the amino acid-containing nanoparticles of the present invention in the preparation of a drug for treating spinal cord injury.
[0054] A fourth aspect of the present invention provides a use of the nanoparticles of the present invention in the preparation of a drug for improving motor function of spinal cord injury.
[0055] A fifth aspect of the present invention provides a use of the nanoparticles of the present invention in the preparation of a drug for protecting and / or repairing spinal cord neurons.
[0056] A sixth aspect of the present invention provides a use of the nanoparticles of the present invention in the preparation of a drug for inhibiting cell apoptosis.
[0057] According to a preferred embodiment of the present invention, the drug for inhibiting cell apoptosis is a drug for inhibiting the expression of the pro-apoptotic factor Bax and / or promoting the expression of the anti-apoptotic factor bcl-2.
[0058] In the present invention, the administration mode of the nanoparticles can be selected from a wide range, which is exemplary but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the administration mode of the nanoparticles is selected from one or more of oral administration and injection administration.
[0059] In the present invention, the pharmaceutical dosage form prepared by the nanoparticles has a wide range of optional options, which is exemplary but does not limit the scope of the present invention. According to a preferred embodiment of the present invention, the pharmaceutical dosage form is selected from one or more of tablets, pills, powders and injections.
[0060] In the context and embodiments of the present invention, in order to calculate the Lys loading rate and release rate, a standard curve of Lys concentration-absorbance at 205 nm was made, Lys was dissolved in ultrapure water, and the absorbance of different concentrations of Lys at 205 nm was tested to obtain Figure 4 The standard curve shown shows that the Lys concentration is linearly correlated with the absorbance, wherein the linear correlation coefficient is R=0.9988.
[0061] In the context and embodiments of the present invention, the method for calculating the Lys loading rate is as follows: the solution of polydopamine and basic amino acids is centrifuged, and the supernatant is used to test the loading rate; the Lys concentration in the supernatant after centrifugation is calculated to determine the mass of Lys in the supernatant. The total mass of Lys is m 总 The mass of Lys in the supernatant after centrifugation is m 上 , Lys loading rate = (m 总 -m 上 ) / m 总 *100%.
[0062] Lys release rate calculation method: Lys-PDA was dissolved in ultrapure water, and the Lys concentration in the solution was measured every 1 h to determine the mass m of Lys in the solution. 溶 , Lys release rate = m 溶 / M*100%, M is the total mass of Lys in Lys-PDA powder.
[0063] In order to further understand the present invention, preferred embodiments of the present invention are described below in conjunction with examples. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the present invention.
[0064] In the following examples, unless otherwise specified, all are conventional experimental methods; the experimental consumables used are from conventional distributors.
[0065] In the following preparation examples and embodiments, Figure 1-Figure 5 In the present invention, PDA refers to a single substance of polydopamine; Lys refers to a single substance of lysine; Lys-PDA refers to nanoparticles containing lysine;
[0066] Figure 6-Figure 12 Sham is the sham operation group; SCI is the spinal cord injury group; PDA is the polydopamine treatment group; Lys is the lysine treatment group, and Lys-PDA is the lysine-containing nanoparticle treatment group.
[0067] In the following preparation examples, polydopamine was prepared by the following method:
[0068] At room temperature, 40 mL of anhydrous ethanol, 2 mL of ammonia (30%) and 90 mL of ultrapure water were added to a round-bottom flask and stirred thoroughly with a magnetic stirrer. Subsequently, 40 mL of 0.025 g / mL dopamine solution was added and stirred for 24 hours to obtain a PDA nanoparticle dispersion, which was centrifuged at 15,000 rpm for 10 minutes, washed, and centrifuged again at 15,000 rpm for 10 minutes. The solid obtained by centrifugation was freeze-dried to obtain PDA powder.
[0069] Preparation Example 1
[0070] Take 1g PDA powder, dissolve it in 20mL deionized water, add 200mg Lys powder, stir for 24 hours, centrifuge (15000rpm, 10 minutes), take the supernatant, and detect the mass of Lys in the supernatant. The loading rate is 69% obtained by the above calculation method. The solid is freeze-dried to obtain polydopamine-loaded lysine nanoparticles (Lys-PDA) powder.
[0071] The PDA powder and the Lys-PDA powder obtained in Preparation Example 1 were observed using a scanning electron microscope. Figure 1 As shown, the structure of PDA is complete, and it is monodisperse round and elliptical particles. The surface of the nanoparticles is flat, and the particle size is about 150nm, and the particle size is uniform. Lys-PDA is also monodisperse round and elliptical particles with uniform size. Compared with PDA, the particle size of Lys-PDA is slightly larger. Lys is observed on the surface of Lys-PDA in the form of a film wrapped around the surface of PDA, forming a white film-like covering layer.
[0072] The particle size of the particles was measured using dynamic light scattering, and the average particle size of PDA was 148 nm. Figure 2 As shown in the figure, compared with PDA, the particle size of Lys-PDA increased due to the loading of Lys, with an average particle size of 175 nm. The increase in particle size also indicates the successful loading of Lys.
[0073] PDA and Lys-PDA prepared in Preparation Example 1 were subjected to Fourier transform infrared spectroscopy analysis. The infrared spectra are shown in FIG. Figure 3As shown in the figure, the phenomenon that the PDA absorption peak changes from 3270nm to 3407nm can be inferred that Lys is successfully bound to PDA. In infrared spectroscopy, the position of the absorption peak is determined by the vibration frequency of the intramolecular bond. In this case, the change of the absorption peak from 3270nm to 3407nm wavelength means that the environment of a specific functional group in the molecule has changed, indicating that the binding of Lys causes the functional groups in the PDA molecule to form hydrogen bonds or other interactions, thereby changing their vibration frequency. Therefore, this change can prove that Lys is successfully bound to the PDA surface.
[0074] After Lys-PDA is dissolved, Lys will be released slowly over time. The drug release capacity of Lys-PDA is determined by Lys release experiment. The test results are as follows: Figure 5 As shown, within 0-6 hours, the release rate of Lys is very fast, and the average release rate of Lys is calculated to be 33.51%±2.258. Within 1-3 days, the release of Lys tends to be slow, and the average release rate of Lys is calculated to be 93.68%±0.756. The above results show that after lysine is loaded on polydopamine, the obtained Lys-PDA nanoparticles have a sustained release effect on lysine.
[0075] 1. Establishment of SCI animal model and drug administration
[0076] 1. In the following examples, 6-8 week old C57BL6 / J mice (provided by Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd.) were used, approved by the Animal Ethics Review Committee, and raised in the Experimental Animal Center of Gannan Medical University.
[0077] 2. In order to explore the improvement and therapeutic effect of the Lys-loaded PDA nanoparticles of the present invention on SCI mice, the specific implementation groups are as follows:
[0078] In the SCI group (spinal cord injury group, n=12), mice were subjected to SCI modeling: under 1.5% isoflurane anesthesia, skin incision was performed, fascia and muscle tissue were separated, laminectomy was performed, spinal cord percussion was performed, and a microsyringe was fixed on a stereotaxic apparatus to slowly (2 minutes) inject 10 μL of PBS solution in situ, and the muscle and skin were sutured layer by layer. After the operation, the mouse hind limbs were massaged and artificial urination was performed twice a day in the morning and evening until the bladder function was restored.
[0079] In the sham group (n=12), mice only received laminectomy without spinal cord percussion: under 1.5% isoflurane anesthesia, after skin incision, fascia and muscle tissue were separated, followed by laminectomy without spinal cord percussion. A microsyringe was fixed on a stereotaxic apparatus and 10 μL of PBS solution was slowly (2 minutes) injected in situ, and the muscle and skin were sutured layer by layer. After surgery, the hind limbs of the mice were massaged and artificial urination was performed twice a day in the morning and evening until the bladder function was restored.
[0080] PDA group (polydopamine injection treatment group, n=12): under 1.5% isoflurane anesthesia, skin incision was performed, fascia and muscle tissue were separated, laminectomy was performed, spinal cord percussion was performed, and a microsyringe was fixed on a brain stereotaxic apparatus to slowly (2 minutes) inject 10 μL of PDA solution (1 mg / ml) in situ, and the muscle and skin were sutured layer by layer. After the operation, the mouse hind limbs were massaged and artificial urination was performed twice a day in the morning and evening until the bladder function was restored.
[0081] Lys group (lysine injection treatment group, n=12): under 1.5% isoflurane anesthesia, skin incision was performed, fascia and muscle tissue were separated, laminectomy was performed, spinal cord percussion was performed, and a microsyringe was fixed on a brain stereotaxic apparatus to slowly (2 minutes) inject 10 μL of Lys solution (1 mg / ml) in situ, and the muscle and skin were sutured layer by layer. After the operation, the mouse hind limbs were massaged and artificial urination was performed twice a day in the morning and evening until the bladder function was restored.
[0082] Lys-PDA group (lysine-containing polydopamine nanoparticle injection treatment group, n=12): under 1.5% isoflurane anesthesia, skin incision was performed, fascia and muscle tissue were separated, laminectomy was performed, spinal cord percussion was performed, and a microsyringe was fixed on a brain stereotaxic apparatus to slowly (2 minutes) inject 10 μL of Lys-PDA solution (1 mg / ml) in situ, and the muscle and skin were sutured layer by layer. After the operation, the mouse hind limbs were massaged and artificial urination was performed twice a day in the morning and evening until the bladder function was restored.
[0083] Example 1
[0084] This example is used to illustrate the effect of Lys-PDA on the acidic microenvironment of spinal cord tissue after spinal cord injury.
[0085] Preparation of frozen sections of spinal cord tissue: Spinal cord tissue was collected and washed with pre-cooled PBS solution, and excess water on the surface was absorbed with absorbent paper. Without dehydration, the spinal cord tissue was quickly fixed on the frozen section sample holder with OCT. When fixing, pay attention to adjust the position of the tissue to obtain a suitable section. Continuous sections were made using a Leica cryostat with a section thickness of 5 μm, and the sections were collected on slides for subsequent operations.
[0086] BCECF-AM fluorescence staining method: After the spinal cord tissue is frozen and sectioned, the spinal cord tissue is stained using Biyuntian BCECF-AM (pH fluorescent probe). BCECF-AM is a fluorescent dye that can penetrate the cell membrane. BCECF-AM itself has no fluorescence. After entering the cell, it is cleaved by esterases in the cell to form BCECF, which is then retained in the cell. BCECF can be excited to form green fluorescence under appropriate pH conditions. The fluorescence intensity of the frozen sections of the spinal cord tissue of each group on the 1st and 28th days was statistically analyzed to reflect the changes in the acidic microenvironment of the spinal cord tissue.
[0087] The frozen sections of the spinal cord tissues of the mice in each group were stained with BCECF-AM fluorescence. Figure 6 As shown in A; after spinal cord injury, the fluorescence of the SCI group, PDA group, Lys group and Lys-PDA group was weakened compared with the Sham group. Figure 6 The fluorescence intensity bar graph in B reflects the significant acidification of the tissue after spinal cord injury (P<0.05). Figure 6 B shows that there was no statistically significant difference in fluorescence intensity among the spinal cord injury groups on the first day after spinal cord injury, which indirectly reflects the success of the model. Figure 6 In A, the fluorescence on the 28th day was observed. The tissues of the SCI group still had obvious acidification on the 28th day. The fluorescence of the Lys group and the Lys-PDA group was restored after different treatment interventions, such as Figure 6 As shown in C, the fluorescence intensity of the Lys group and Lys-PDA group was significantly enhanced compared with the SCI group (P<0.05); among them, the fluorescence intensity of the Lys-PDA group was further significantly enhanced compared with the Lys group (P<0.05), indicating that the acidic microenvironment of the spinal cord tissue was improved after Lys and Lys-PDA treatment, and the recovery effect of the pH balance of the mouse spinal cord tissue after Lys-PDA treatment was better than that after Lys treatment.
[0088] Example 2
[0089] This example is used to illustrate the effect of Lys-PDA on the motor function of spinal cord injury.
[0090] Each group of mice was trained for footprint analysis before spinal cord injury: the mice were placed in a long and narrow passage, about 1m in length, with a dark shelter area at the end of the passage, and sufficient food and water were provided. At 1d, 3d, 7d, 14d, 21d, and 28d after modeling, researchers who were not familiar with the mouse grouping scored the modeled mice with the Bassomouse scale (BMS) to evaluate the motor function of the mice after injury. The mice were placed on an open plane and scored 0 to 9 points (9 points for complete normality and 0 points for complete paralysis) based on the range of motion, paw position, trunk stability, hind limb and tail position. Each mouse was measured 3 times and the average was taken, each time for 5 minutes. Mice with a BMS score greater than 1 on the first day after SCI modeling were removed. After 28 days, the front paws of the mice were soaked in blue ink and the hind paws were soaked in red ink, and then placed in a narrow passage. The step length was measured and analyzed by collecting continuous front and hind paw footprints.
[0091] Footprint behavior analysis of mice in each group on day 28 was as follows Figure 7 As shown, Figure 7 In A, the hind paw prints of mice in the Sham group were obvious, with the longest forefoot stride, while the mice in the SCI group could only drag their hind limbs at 28 days, with a significantly shortened forefoot stride. The PDA, Lys, and Lys-PDA groups showed that the stability and coordination of mice with spinal cord injury were improved after treatment. Figure 7 C is a bar graph showing the statistical length of forelimb stride of mice in each group. It can be seen that after drug treatment, compared with the SCI group, the forelimb stride of mice in the PDA group, Lys group and Lys-PDA group was significantly increased (P<0.05). Among them, the forelimb stride of mice in the Lys-PDA group was further significantly increased compared with that in the PDA group and Lys group (P<0.05), indicating that the stability and coordination improvement effect of mice in the Lys-PDA group was the best.
[0092] Figure 7 B is a line graph of the BMS scores of mice in each group. The BMS scoring criteria are shown in Table 1. On the first day after surgery, the BMS scores of all groups were 0, indicating that the model was successfully established and the model was well homogenized; the score of mice in the Sham group was 9, indicating that the motor function of the hind limbs was completely normal; Figure 7 B shows that the BMS scores of mice in each group increased after surgery, indicating that mice in each group recovered to a certain extent after spinal cord injury.
[0093] On the 7th day, the mean BMS scores of the Sham group, SCI group, PDA group, Lys group and Lys-PDA group were 9, 0.5, 1.2, 1.2 and 1.3 points, respectively. Compared with the SCI group, the score of the Lys-PDA group was significantly increased (P<0.01). On the 14th day, the mean BMS scores of each group were 9, 0.8, 2.2, 2 and 2.7 points, respectively. Compared with the SCI group, the BMS scores of the Lys-PDA group and the Lys group were significantly increased (P<0.05). Among them, the score of the Lys-PDA group was further significantly increased compared with the Lys group (P<0.05). On the 21st day, the average BMS scores of each group were 9, 1.3, 2.7, 2.3 and 4.7 points, respectively. There were significant differences in the BMS scores between Lys-PDA and SCI, PDA and Lys groups (P<0.001), indicating that the recovery of the hind limbs of mice in the Lys-PDA group was significantly better than that in other treatment groups. On the 28th day, the average BMS scores of each group were 9, 1.5, 3.2, 2.7 and 5.8 points, respectively. The status of the PDA and Lys groups began to stabilize, and the BMS scores did not change significantly compared with the 21st day, while the BMS scores of mice in the Lys-PDA group still increased, indicating that Lys-PDA has the best therapeutic effect on the motor function of mice with spinal cord injury. The BMS score of the Lys-PDA group was the highest in all time periods after the 7th day. Compared with the PDA group and the Lys group, the BMS score of the Lys-PDA group was most significantly higher than that of the SCI group, indicating that the treatment effect of Lys-PDA was significant and the hind limb function of mice was significantly improved.
[0094] Table 1
[0095]
[0096] Example 3
[0097] This example is used to illustrate the effect of Lys-PDA on spinal cord neurons.
[0098] H&E staining method: spinal cord tissues of mice in each group were fixed in 4% paraformaldehyde, embedded in paraffin and sliced, with a slice thickness of 5μm. The slices were immersed in 56% xylene for 20 minutes for dewaxing, and after dewaxing twice, they were hydrated with ethanol 4 times (twice 100%, once 95%, and once 75% ethanol) for 5 minutes each. Hematoxylin and eosin staining: the slices were immersed in 0.5% glacial acetic acid solution for 10 minutes, hematoxylin staining for 8 minutes, rinsed with tap water for 1 minute, differentiated with 1% hydrochloric acid ethanol for 5 seconds, observed the cell nucleus staining under a microscope, flow-through colorimetric for 1 hour, immersed in 95% ethanol for 5 minutes, eosin staining for 1 minute, and rinsed with distilled water for 1 minute. The slices were placed in 95% ethanol and anhydrous ethanol twice, each for 3 minutes, transparent in xylene for 15 minutes twice, sealed with neutral gum, and examined under a microscope.
[0099] H&E staining was performed on the spinal cord tissue sections of each group of mice. The staining results are shown in Figure 8 As shown in the figure, the Sham group showed a normal state of spinal cord tissue. According to the staining of the SCI group mice, it can be seen that the density of spinal cord neuron cells in the mice was significantly reduced, the tissue arrangement was seriously disordered, a large number of cells died, and there was obvious nuclear condensation. After drug treatment, the staining of the PDA group and the Lys group showed that the disorder of spinal cord tissue was improved, but there were still large spinal cord cavities; in the Lys-PDA group, the above situation was further improved, the spinal cord cavities and tissue disorder were further alleviated, and the damaged spinal cord tissue showed more signs of repair. The above results prove that Lys-PDA can effectively improve the damage to spinal cord neurons caused by spinal cord injury, and the retention and regeneration of spinal cord neurons in each group were verified by Nissl staining.
[0100] Nissl staining can specifically stain nerve cell bodies and is extremely useful for identifying and evaluating the state of neurons in the spinal cord injury area. After spinal cord injury, nerve cells will undergo a variety of morphological and structural changes, and changes in the number of Nissl bodies can reflect the metabolic and functional state of the cells. By comparing the number of Nissl bodies and morphological changes of neurons in each group, the degree of spinal cord injury can be evaluated to reflect the treatment effect.
[0101] The spinal cord tissue sections of each group of mice were Nissl stained. The Nissl staining method was as follows: the spinal cord tissue sections of each group of mice were placed in Toluidine blue dye, placed in a constant temperature box at a temperature of 50-60°C, and infected for 25-50 minutes. After being rinsed with distilled water, the sections were rinsed in 70% ethanol, and then quickly placed in 95% ethanol for differentiation. The sections were placed in anhydrous ethanol for dehydration, transparentized with xylene, and then sealed with neutral gum for microscopic examination.
[0102] Nissl staining results Fig. 9As shown in A, the density of spinal cord neurons in the Sham group mice was normal; while the neuronal structure of the SCI group mice showed that the neuronal cell bodies became smaller, and the cell nuclei underwent nuclear condensation, nuclear fragmentation, and nuclear dissolution; Fig. 9 B is a bar graph showing the number of Nissl cells. Compared with the Sham group, the number of normal-shaped Nissl-positive cells in the spinal cord tissue of the SCI group was significantly reduced (P<0.001). Compared with the SCI group, the number of Nissl-positive cells in the Lys-PDA group was significantly increased (P<0.001). The above results indicate that Lys-PDA can alleviate SCI-induced spinal cord neuron damage, reduce neuronal degeneration, and preserve more neurons.
[0103] Example 4
[0104] This example is used to illustrate the effect of Lys-PDA on apoptosis of spinal cord tissue cells.
[0105] To evaluate the apoptosis of spinal cord tissue in each group of mice, TUNEL staining was performed on the spinal cord tissue of each group of mice 28 days after spinal cord injury. Fig.10 As shown in A, the nuclei of TUNEL-positive cells showed green fluorescent particles, reflecting cell apoptosis. Occasional cell apoptosis was observed in the Sham group, while more apoptotic cells were observed in the SCI group, PDA group, and Lys group. Fig.10 B is a statistical bar graph of the mean fluorescence intensity of mice in each group, showing that there was a significant difference in the mean fluorescence intensity between the Lys-PDA group and the SCI group, PDA group, and Lys group (P<0.05); that is, the number of positive cells in the Lys-PDA group was significantly reduced compared with the SCI group, PDA group, and Lys group, indicating that cell apoptosis was alleviated after Lys-PDA treatment.
[0106] The role of BAX in spinal cord injury mainly involves regulating cell apoptosis. As a pro-apoptotic protein, the upregulation of BAX in damaged nerve cells can promote cell death, thereby affecting the recovery process after spinal cord injury. As a major anti-apoptotic protein, bcl-2 can inhibit programmed cell death. By inhibiting the pathway of cell apoptosis, bcl-2 reduces the death of nerve cells after spinal cord injury and helps to protect and maintain the function of the spinal cord.
[0107] The expression of Bax and bcl-2 proteins in the spinal cord tissues of each group of mice was detected by Western Blot experiment. Fig.11 A is the Western Blot band diagram, which shows that compared with the SCI group, the expression of the pro-apoptotic protein Bax in the Lys-PDA group was weakened, and the expression of the anti-apoptotic protein bcl-2 was enhanced. Fig.11 B and C are the qualitative analysis bar graphs of the expression of bcl-2 and Bax, Fig.11In B, compared with the SCI group mice, the expression levels of bcl-2 in the PDA group and the Lys group were significantly increased; compared with the PDA group and the Lys group, the expression level of bcl-2 in the Lys-PDA group was further significantly increased (P<0.05). Fig.11 In C, compared with the SCI group, the expression of Bax in the PDA group and the Lys group was significantly reduced; the expression of Bax in the Lys-PDA group was further significantly reduced compared with the PDA group and the Lys group (P<0.05). The above results show that Lys and PDA drug treatment can inhibit the pro-apoptotic factor Bax and promote the expression of the anti-apoptotic factor bcl-2, achieving the anti-apoptotic effect; and after PDA was loaded with Lys, the anti-apoptotic effect of Lys-PDA treatment was further enhanced.
[0108] Example 5
[0109] This example is used to illustrate the biocompatibility of Lys-PDA.
[0110] After the mice were dissected, the tissue structures of the heart, liver, spleen, lung, and kidney of each group of mice were observed and evaluated. Fig.12 As shown, under the microscope, no congestion, edema or necrosis was observed in the hearts of mice in each group; no fatty degeneration or drug enrichment was observed in the liver; the structure of the glomeruli and renal tubules was normal, with no significant difference compared with the Sham group, and no drug accumulation was found; no significant difference was observed in the spleen and lungs compared with the Sham group; this indicates that the good biocompatibility of the drug itself and the in situ injection method at the site of spinal cord injury significantly reduce the concentration of the drug in the blood circulation, thereby significantly reducing the accumulation in various organs and significantly reducing the toxic side effects of nanoparticles and other drugs, indicating that Lys-PDA nanoparticles have good biocompatibility, laying the foundation for the systematic evaluation of Lys-PDA nanoparticles.
[0111] The results of the above embodiments show that the Lys-PDA nanoparticles have a high Lys loading rate and can achieve a three-day slow release of Lys under in vitro conditions. Lys-PDA is used to prepare drugs for the treatment of SCI, which has an improvement effect on the acidic microenvironment of tissues in SCI and can improve the motor function of SCI mice. Under the drug treatment of Lys-PDA, the morphology and arrangement of neurons in the spinal cord tissue of mice, the density and morphology of glial cells are closer to normal spinal cord tissue, and the damaged nerve tissue shows more signs of repair, indicating that Lys-PDA can reduce the occurrence of tissue cavitation and tissue disorder; at the same time, the cell body size, nucleolus size and morphology of neurons in the spinal cord tissue are closer to the morphology of neurons in the normal state, and more neurons are retained. TUNEL staining also showed that neuronal apoptosis was alleviated and the survival rate was improved, indicating that Lys-PDA promoted the survival and regeneration of neurons. Western Blot detection showed that after Lys-PDA drug treatment, the expression of the anti-apoptotic protein Bcl-2 in SCI mice was enhanced, and the expression level of the pro-apoptotic protein Bax was reduced, further verifying that Lys-PDA can inhibit cell apoptosis after SCI and has a neuroprotective effect. In summary, the amino acid-containing nanoparticles of the present invention are used to prepare drugs for treating spinal cord injury, which can effectively improve the acidic microenvironment of tissues after spinal cord injury, and have the effects of promoting motor function recovery after spinal cord injury, repairing damaged nerves and inhibiting cell apoptosis.
[0112] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
Claims
1. A nanoparticle containing amino acids, characterized in that: The nanoparticles include polydopamine and basic amino acids loaded on the polydopamine.
2. The nanoparticle according to claim 1, wherein The basic amino acid is selected from one or more of arginine, lysine and histidine, preferably lysine; and / or The polydopamine is a homopolymer of dopamine hydrochloride oxidatively polymerized under alkaline conditions.
3. The nanoparticle according to claim 1 or 2, wherein The average particle size of the nanoparticles is 120-200 nm.
4. The method for preparing nanoparticles according to any one of claims 1 to 3, characterized in that: The method includes: In a solvent, polydopamine and basic amino acid are mixed and stirred, solid-liquid separation is performed to remove liquid, and drying is performed.
5. The preparation method according to claim 4, wherein The loading rate of basic amino acids is 68.89% ± 0.5%; and / or The stirring conditions include: stirring time of 12-36h; stirring temperature of 25-50°C; and / or The solvent is selected from water and / or ethanol; and / or The drying method is freeze drying; and / or The average particle size of the polydopamine is 100-200 nm; and / or The preparation method of polydopamine comprises: polymerizing dopamine hydrochloride in the presence of an alkali solution, separating to obtain a solid, and drying; The alkali solution is selected from ammonia water and / or sodium hydroxide solution; preferably ammonia water, more preferably, the mass concentration of ammonia water is 25wt%-28wt%.
6. Use of the nanoparticles according to any one of claims 1 to 3 in the preparation of a drug for treating spinal cord injury.
7. Use of the nanoparticles according to any one of claims 1 to 3 in the preparation of a drug for improving motor function in spinal cord injury.
8. Use of the nanoparticles according to any one of claims 1 to 3 in the preparation of a drug for protecting and / or repairing spinal cord neurons.
9. Use of the nanoparticles according to any one of claims 1 to 3 in the preparation of a drug for inhibiting cell apoptosis; Preferably, the drug for inhibiting cell apoptosis is a drug for inhibiting the expression of pro-apoptotic factor Bax and / or promoting the expression of anti-apoptotic factor bcl-2.
10. The use according to any one of claims 6 to 9, wherein: The nanoparticles are administered in a manner selected from one or more of oral administration and injection administration; and / or The pharmaceutical dosage form is selected from one or more of tablets, pills, powders and injections.
